These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28577949)

  • 61. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.
    Li M; Li C; Ke L; Zhan M; Cheng M
    Oncol Lett; 2018 Dec; 16(6):7057-7067. PubMed ID: 30546439
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.
    Akamine T; Tagawa T; Ijichi K; Toyokawa G; Takamori S; Hirai F; Okamoto T; Oda Y; Maehara Y
    Ann Surg Oncol; 2019 May; 26(5):1544-1551. PubMed ID: 30798450
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
    Aokage K; Miyoshi T; Wakabayashi M; Ikeno T; Suzuki J; Tane K; Samejima J; Tsuboi M
    Lung Cancer; 2021 Oct; 160():8-16. PubMed ID: 34365179
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas.
    Hu SY; Hsieh MS; Hsu HH; Tsai TM; Chiang XH; Tsou KC; Liao HC; Lin MW; Chen JS
    Lung Cancer; 2018 Dec; 126():189-193. PubMed ID: 30527186
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.
    Isaka T; Yokose T; Ito H; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Nakayama H; Masuda M
    Medicine (Baltimore); 2015 Oct; 94(42):e1784. PubMed ID: 26496308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.
    Ito M; Miyata Y; Hirano S; Irisuna F; Kushitani K; Kai Y; Kishi N; Tsutani Y; Takeshima Y; Okada M
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1419-1428. PubMed ID: 34218331
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Analysis of EGFR mutation and clinical features of lung cancer in Yunnan].
    Zhou YC; Lin YP; Li Q; Ma LY; Liu X; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Dai M; Zhang Q
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):729-734. PubMed ID: 32988154
    [No Abstract]   [Full Text] [Related]  

  • 68. Epidermal growth factor receptor (EGFR) mutation testing is useful for primary lung cancer diagnosis and appropriate surgical resection: A case series.
    Kitamura A; Ishii K; Okafuji K; Kojima F; Bando T
    Respir Investig; 2022 Jan; 60(1):171-175. PubMed ID: 34544656
    [TBL] [Abstract][Full Text] [Related]  

  • 69. DNMT3a expression pattern and its prognostic value in lung adenocarcinoma.
    Husni RE; Shiba-Ishii A; Iiyama S; Shiozawa T; Kim Y; Nakagawa T; Sato T; Kano J; Minami Y; Noguchi M
    Lung Cancer; 2016 Jul; 97():59-65. PubMed ID: 27237029
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Surgical Treatment and Prognosis for Patients with 
Synchronous Multiple Primary Lung Adenocarcinomas].
    Peng Y; Wang H; Xie H; Ren W; Feng Z; Li M; Peng Z
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):107-113. PubMed ID: 28228222
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer.
    Chen Z; Zhang J; Huang K; Shen Q; Teng X
    Int J Clin Exp Pathol; 2018; 11(9):4644-4649. PubMed ID: 31949864
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Current status of postoperative pathological diagnosis of lung cancer in China: a multicenter big data study].
    ;
    Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):882-890. PubMed ID: 34344071
    [No Abstract]   [Full Text] [Related]  

  • 73. Efficacy of platinum-based adjuvant chemotherapy for epidermal growth factor receptor-mutant lung adenocarcinoma.
    Onodera K; Yokota I; Matsumura Y; Hayasaka K; Shiono S; Abe J; Notsuda H; Sakurada A; Suzuki H; Okada Y
    J Thorac Dis; 2023 Dec; 15(12):6534-6543. PubMed ID: 38249908
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic analysis of patients with mutant and wild-type
    Zheng H; Zhang Y; Zhan Y; Liu S; Lu J; Feng J; Wu X; Wen Q; Fan S
    Cancer Manag Res; 2019; 11():6139-6150. PubMed ID: 31308750
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Persistent increase and improved survival of stage I lung cancer based on a large-scale real-world sample of 26,226 cases.
    Wang C; Shao J; Song L; Ren P; Liu D; Li W
    Chin Med J (Engl); 2023 Aug; 136(16):1937-1948. PubMed ID: 37394562
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II-III.
    Kawaguchi Y; Okano T; Imai K; Maehara S; Maeda J; Yoshida K; Hagiwara M; Kakihana M; Kajiwara N; Ohira T; Matsubayashi J; Ikeda N
    Oncol Lett; 2019 Dec; 18(6):6451-6458. PubMed ID: 31807168
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection.
    Chen S; Yang S; Zhang Y; Xiang J; Zhang Y; Hu H; Sun Y; Fu F; Deng C; Wang S; Li Q; Gu Y; Li Y; Shen X; Ye T
    J Thorac Dis; 2021 Sep; 13(9):5496-5507. PubMed ID: 34659816
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma.
    Deng C; Zhang Y; Fu F; Ma X; Wen Z; Ma Z; Wang S; Li Y; Chen H
    Eur J Cardiothorac Surg; 2021 Nov; 60(5):1223-1231. PubMed ID: 34172990
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Expression of colony-stimulating factor 1 in lung adenocarcinoma and its prognostic implication].
    Pei B; Sun B; Zhang Y; Wang A; Zhang Z
    Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):113-8. PubMed ID: 25975687
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
    Shlomi D; Abud M; Liran O; Bar J; Gai-Mor N; Ilouze M; Onn A; Ben-Nun A; Haick H; Peled N
    J Thorac Oncol; 2017 Oct; 12(10):1544-1551. PubMed ID: 28709937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.